openheart

Combined anticoagulant and antiplatelet therapy is associated with an improved outcome in hospitalised patients with COVID-19: a propensity matched cohort study

Kamal Matli,[1,2] Nibal Chamoun [ID],[3] Aya Fares,[2] Victor Zibara,[4] Soad Al-Osta,[4] Rabih Nasrallah,[2] Pascale Salameh,[5,6] Jacques Mokhbat,[2,4] Georges Ghanem [ID] [1,4]

AF and VZ contributed equally. SA-O and RN contributed equally.

JM and GG are joint senior authors.

Check for updates

For numbered affiliations see end of article.

Correspondence to
Dr Georges Ghanem; gghanemresearch@gmail.com

ABSTRACT

Background COVID-19 is a respiratory disease that results in a prothrombotic state manifesting as thrombotic, microthrombotic and thromboembolic events. As a result, several antithrombotic modalities have been implicated in the treatment of this disease. This study aimed to identify if therapeutic anticoagulation (TAC) or concurrent use of antiplatelet and anticoagulants was associated with an improved outcome in this patient population.

Methods A retrospective observational cohort study of adult patients admitted to a single university hospital for COVID-19 infection was performed. The primary outcome was a composite of in-hospital mortality, intensive care unit (ICU) admission or the need for mechanical ventilation. The secondary outcomes were each of the components of the primary outcome, in-hospital mortality, ICU admission, or the need for mechanical ventilation.

Results 242 patients were included in the study and divided into four subgroups: Therapeutic anticoagulation (TAC), prophylactic anticoagulation +antiplatelet (PACAP), TAC +antiplatelet (TACAP) and prophylactic anticoagulation (PAC) which was the reference for comparison. Multivariable Cox regression analysis and propensity matching were done and showed when compared with PAC, TACAP and TAC were associated with less in-hospital all-cause mortality with an adjusted HR (aHR) of 0.113 (95% CI 0.028 to 0.449) and 0.126 (95% CI 0.028 to 0.528), respectively. The number needed to treat in both subgroups was 11. Furthermore, PACAP was associated with a reduced risk of invasive mechanical ventilation with an aHR of 0.07 (95% CI 0.014 to 0.351). However, the was no statistically significant difference in the occurrence of major or minor bleeds, ICU admission or the composite outcome of in-hospital mortality, ICU admission or the need for mechanical ventilation.

Conclusion The use of combined anticoagulant and antiplatelet agents or TAC alone in hospitalised patients with COVID-19 was associated with a better outcome in comparison to PAC alone without an increase in the risk of major and minor bleeds. Sufficiently powered randomised controlled trials are needed to further evaluate the safety and efficacy of combining antiplatelet and anticoagulants agents or using TAC in the management of patients with COVID-19 infection.

Key questions

What is already known about this subject?

► COVID-19 infection is associated with several complex coagulation disorders resulting in thrombotic, microthrombotic and thromboembolic events. Currently, prophylactic dose anticoagulation is considered the standard of care antithrombotic regimen in hospitalised patients with COVID-19. However, high-quality data about the subject is unavailable.

What does this study add?

► This is the first adequately sized study in the literature to dwell on the antithrombotic strategy consisting of combination anticoagulant and antiplatelet therapy in the treatment of COVID-19 induced hypercoagulable state. Furthermore, it also challenges the currently recommended prophylactic dosing of anticoagulation used in the treatment of those patients.

How might this impact on clinical practice?

► Our data suggest for the first time that concurrent use of anticoagulant and antiplatelet therapy is associated with a superior clinical outcome as compared with prophylactic anticoagulation (PAC) used alone. Furthermore, it solidifies the emerging evidence that therapeutic anticoagulation is linked to better clinical results than PAC.

INTRODUCTION

SARS-CoV-2 has infected over 184 million people and caused over 3.9 million deaths worldwide according to the latest report on 5 July by the WHO.[1] Although the respiratory symptoms are the primary clinical manifestations of the disease, patients may experience thrombotic complications associated with increased mortality.[2–4] COVID-19 also increases cardiovascular disease (CVD), such as myocardial injury, acute coronary syndrome, in addition to venous and arterial

thromboembolic events, such as pulmonary embolism (PE), deep venous thrombosis (DVT), arterial thrombosis, catheter thrombosis and disseminated intravascular coagulopathy.[5–10]

Evidence of hypercoagulability has been observed in markers of coagulation found in patients with COVID-19 such as elevated D-dimer and fibrinogen concentration.[11] Coagulation in the human body is a complex cascade that involves the interaction between endothelial cells, platelets and coagulation factors.[12] Under normal conditions, platelets circulate in the bloodstream without adhering to the intact and inactive endothelium and most of the clotting factors circulate in an inactive form.[13] However, COVID-19 infection was shown to be highly associated with endothelial dysfunction favouring a proinflammatory and procoagulant state.[14] Infection with this virus leads to subsequent endothelial activation and dysfunction due to disruption of the vascular integrity, leading to endothelial cell apoptosis. This exposes the thrombogenic basement membrane into the circulation and activates the clotting cascade by displaying Von Willebrand Factor, P-selectin and fibrinogen, onto which activated platelets bind and play their primary role in thrombosis.[15]

In addition to the platelet clotting activation, the coagulation cascade is also activated in COVID-19 infected patients.[16] This can occur via two mechanisms.[15] The first mechanism is through the activated platelets that produce vascular endothelial growth factor, which induces endothelial cells to express tissue factor, the main activator of the coagulation cascade. The second mechanism of activation occurs as a direct result of virus induced vessel injury. This is translated clinically into heightened

coagulopathy that manifests as microvascular, venous and arterial thrombosis.[17–19]

Different treatment modalities have been implicated in the treatment of COVID-19 hypercoagulable state with the best agent still undefined. Current guidelines recommend the use of prophylactic dose anticoagulation in all patients hospitalised with COVID-19 infection.[20 21] However, these recommendations are based on low certainty evidence.

Ongoing clinical trials aim to evaluate the effect of prophylactic and therapeutic anticoagulation (TAC) therapy on survival and adverse events.[22] Preliminary data on anticoagulant therapy shows that it appears to be associated with better outcomes and reduced mortality.[23 24] Furthermore, the role of aspirin was also investigated in patients with COVID-19 in a retrospective observational cohort study of adult patients. It was found to be associated with decreased risk of mechanical ventilation, intensive care unit (ICU) admissions and in-hospital mortality after adjusting for confounders.[25 26]

In this study, we evaluated whether the combination of anticoagulation and antiplatelet therapy or TAC in hospitalised patients with COVID-19 is associated with an improved clinical outcome compared with the standard prophylactic anticoagulation (PAC) therapy alone as currently recommended by the guidelines.[27]

METHODS

Study settings and population

Patients with the diagnosis of SARS-CoV-2 infection, admitted to the Lebanese American University-Rizk Hospital between April 2020 and 31 January 2021, and hospitalised in medical wards or ICU, were included in the study. Patients were included if they were aged 18 years and older with confirmed laboratory diagnosis for COVID-19. In accordance with WHO criteria, confirmed cases of SARS-CoV-2 infections were determined by positive results from real-time reverse transcriptase-PCR that amplifies DNA sequences specific to the virus from either combination of nasal and pharyngeal swabs or lower respiratory tract aspirates.[1] Patients on dual antiplatelet therapy, with an acute venous thromboembolism (VTE) defined as DVT or PE, acute cardiovascular event, acute stroke (ischaemic or haemorrhagic) all within the prior 3 months, or with an active major bleeding, severe thrombocytopenia (<25 000/mm^3), were excluded from this study.

Data collection

All data were collected and screened by local investigators with access to electronic medical records. The patients' baseline information included demographic characteristics, comorbidities, any known allergies and chronic medications. Anticoagulation and antiplatelet therapy on admission was collected, as well as its respective indication. Laboratory results and vital signs were recorded on admission. Clinical parameters, including the type of


**Figure 1** Flowchart of study participants.

Figure 2 Survival function for (A) invasive mechanical ventilation (B) all-cause mortality. Patients are stratified according to antithrombotic regimen used. (A) PACAP was associated with a decreased hazard for receiving invasive mechanical ventilation (aHR=0.070; 95% CI 0.014 to 0.351). (B) TACAP and TAC were associated with less in-hospital all-cause mortality with an aHR of 0.113 (95% CI 0.028 to 0.449) and 0.126 (95% CI 0.028 to 0.528), respectively. aHR, adjusted HR, PAC, prophylactic anticoagulation; PACAP, prophylactic anticoagulation +antiplatelet; TAC, therapeutic anticoagulation; TACAP, therapeutic anticoagulation +antiplatelet.

oxygen therapy were recorded from admission and up until discharge. Data on complications during the hospital stay, COVID-19 specific pharmacological therapies and clinical outcome were collected during hospitalisation. The data collection sheet was designed in accordance with the toolkit for the collection of thrombosis-related data elements in COVID-19 clinical studies.[28] Major

bleeding and clinically relevant non-major bleeding were defined as per the International Society of Thrombosis and Haemostasis (ISTH) and Scientific and Standardization Committee. Major bleeding was bleeding that led to a haemoglobin drop of more than 20 g/L, required more than 2 units of packed red blood cell transfusion, lead to death, intracranial bleeding, retroperitoneal

Table 1 Baseline characteristics and outcomes by antithrombotic treatment exposure status

Variables	Prophylactic anticoagulation n=51	Therapeutic anticoagulation n=31	Prophylactic anticoagulation + antiplatelet therapy n=95	Therapeutic anticoagulation + antiplatelet therapy n= 65	P value
Age, years, mean (SD)	59.69 (17.04)	62.55 (15.80)	66.22 (13.83)	62.66 (14.73)	0.09
Males, n (%)	30 (58.8)	21 (67.7)	64 (67.4)	52 (80.0)	0.1
Females, n (%)	21 (41.2)	10 (32.3)	31 (32.6)	13 (20.0)	
Weight (kg), mean (SD)	78.58 (18.66)	84.26 (23.91)	82.02 (17.01)	88.11 (16.03)	0.04
Smokers, n (%)	14 (27.5)	9 (29.0)	9 (9.5)	21 (32.3)	0.002
Hypertension, n (%)	20 (39.2)	14 (45.2)	55 (57.9)	33 (50.8)	0.17
Dyslipidemia, n (%)	12 (23.5)	8 (25.8)	44 (46.3)	23 (35.4)	0.03
Congestive heart failure, n (%)	2 (3.9)	1 (3.2)	3 (3.2)	6 (9.2)	0.32
Cancer, n (%)	7 (13.7)	5 (16.1)	8 (8.4)	3 (4.6)	0.21
Diabetes mellitus, n (%)	10 (19.6)	8 (25.8)	32 (33.7)	16 (24.6)	0.29
Bleeding disorder, n (%)	1 (2.0)	0 (0)	0 (0)	1 (1.5)	0.52
Liver disease, n (%)	0 (0)	1 (3.2)	1 (1.1)	1 (1.5)	0.63
Kidney disease, n (%)	3 (5.9)	1 (3.2)	2 (2.1)	5 (7.7)	0.37
COPD, n (%)	0 (0)	1 (3.2)	4 (4.2)	2 (3.1)	0.55
CAD, n (%)	1 (2.0)	5 (16.1)	10 (10.5)	10 (15.4)	0.09
Others, n (%)	18 (35.3)	15 (48.4)	34 (35.8)	21 (32.3)	0.49
Home anticoagulation, n (%)	3 (5.9)	9 (29.0)	3 (3.2)	5 (7.7)	<0.001
Indication for anticoagulant use					
Atrial fibrillation, n (%)	1 (2.0)	6 (19.4)	1 (1.1)	3 (4.6)	0.004
Venous thromboembolism, n (%)	1 (2.0)	1 (3.2)	1 (1.1)	1 (1.5)	
Home antiplatelet, n (%)	2 (3.9)	1 (3.2)	25 (26.3)	16 (24.6)	0.001
Indication for antiplatelet use					
Acute coronary syndrome, n (%)	1 (2.0)	1 (32)	2 (3.2)	4 (6.2)	0.06
Post coronary artery bypass grafting, n (%)	0 (0)	0 (0)	5 (5.3)	2 (3.1)	
Others n (%)	1 (2.0)	0 (0)	15 (15.8)	7 (10.8)	
ACEi/ARB, n (%)	8 (15.7)	9 (29.0)	29 (30.5)	20 (30.8)	0.22
Beta blocker, n (%)	13 (25.5)	8 (25.8)	23 (24.2)	19 (29.2)	0.92
Corticosteroids, n (%)	3 (5.9)	1 (3.2)	1 (1.1)	0 (0)	0.13
Antibiotics, n (%)	1 (2.0)	0 (0)	2 (2.1)	2 (3.1)	0.81
Immunosuppressant, n (%)	2 (3.9)	5 (16.1)	6 (6.3)	1 (1.5)	0.04
Dyspnea, n (%)	18 (35.3)	12 (38.7)	47 (49.5)	28 (43.1)	0.61
Fever, n (%)	13 (25.5)	5 (16.1)	15 (15.8)	11 (16.9)	
Cough, n (%)	5 (9.8)	3 (9.7)	6 (6.3)	5 (7.7)	
Desaturation, n (%)	5 (9.8)	5 (16.1)	7 (7.4)	11 (16.9)	
Vomiting, n (%)	2 (3.9)	2 (6.7)	0 (0)	2 (3.1)	
Chest Pain, n (%)	2 (3.9)	1 (3.2)	1 (1.1)	2 (3.1)	
Diarrhea, n (%)	1 (2.0)	1 (3.2)	4 (4.2)	1 (1.5)	
Fatigue, n (%)	3 (5.9)	1 (3.2)	2 (2.1)	1 (1.5)	
Chills, n (%)	0 (0)	1 (3.2)	1 (1.1)	0 (0)	
Myalgia, n (%)	0 (0)	0 (0)	2 (2.1)	0 (0)	
Others, n (%)	2 (3.9)	2 (6.5)	6 (6.3)	4 (6.2)	
Days of symptoms, mean (SD)	4.92 (4.79)	4.63 (4.43)	3.98 (3.82)	4.19 (3.65)	0.58
Oxygen on presentation					

Continued

Table 1 Continued

Variables	Prophylactic anticoagulation n=51	Therapeutic anticoagulation n=31	Prophylactic anticoagulation + antiplatelet therapy n=95	Therapeutic anticoagulation + antiplatelet therapy n= 65	P value
Nasal canula, n (%)	18 (35.3)	10 (32.3)	29 (30.5)	16(24.6)	0.65
Face mask, n (%)	2 (3.9)	4 (12.9)	2 (2.1	6 (9.2)	0.07
Non-rebreather, n (%)	2 (3.9)	3 (9.7)	4 (4.2)	13 (20.0)	0.003
Vitals on admission					
Heart rate, mean (SD)	90.63 (15.07)	64.97 (17.28)	89.56 (13.52)	92.86 (15.03)	0.26
Temperature, mean (SD)	37.70 (1.12)	38.07 (0.99)	37.50 (0.90)	37.74 (1.10)	0.05
Oxygen saturation, mean (SD)*	94.61 (3.20)	89.74 (10.69)	93.25 (5.91)	88.37 (12.73)	0.001
Admissions labs					
Platelet count, mean (SD)	265996 (104433)	262129 (122690)	239052 (111562)	227861 (103930)	0.22
PT, mean (SD)	17.13 (19.16)	16.08 (5.13)	14.06 (2.26)	14.47 (2.66)	0.33
PTT, mean (SD)	31.81 (16.24)	30.19 (4.46)	29.03 (5.45)	32.96 (15.12)	0.28
D-dimers, mean (SD)	1.06 (0.81)	4.60 (7.28)	.90 (0.61)	1.32 (1.47)	<0.001
Admissions labs					
Fibrinogen, mean (SD)*	484 (141.45)	524 (214.64)	511 (131.50)	532. (171.48)	0.42
Troponin, mean (SD)	13.06 (16.34)	32.69 (49.63)	25.52 (64.03)	58.25 (313.92)	0.59
BNP, mean (SD)	391.79 (827.93)	3467.43 (7642.4)	2078.66 (6510.8)	1399.73 (3691.12)	0.48
CRP, mean (SD)	7.24 (6.01)	14.92 (9.01)	6.72 (5.84)	10.69 (9.56)	<0.001
WBC, mean (SD)*	11951 (34879)	8648 (5384)	6630 (2816)	7875 (3428)	0.11
Lymphocyte, mean (SD)	946 (977.27)	884 (632.13)	941 (1186.50)	662 (380.87)	0.24
Interluekin-6 Levels, mean (SD)	85.33 (208.08)	114.80 (96.301)	62.07(85.48)	277.53 (713.05)	0.03
VTE Risk (Padua score)					
Padua score >4, n (%)	9 (17.6)	10 (32.3)	13 (13.7)	8 (12.3)	0.07
Padau score < 4, n (%)	42 (82.4)	21 (67.7)	82 (86.3)	57 (87.7)	
Bleeding risk (IMPROVE bleeding risk score)					
Score < 7, n (%)	50 (98.0)	29 (93.5)	92 (96.8)	62 (95.4)	0.73
Score >7, n (%)	1 (2.0)	2 (6.5)	3 (3.2)	3 (4.6)	
COVID-19 hospital administered medications					
Steroids, n (%)	42 (82.4)	31 (100)	86 (90.5)	64 (98.5)	0.004
Tofacitinib, n (%)	2 (3.9)	6 (19.4)	3 (3.2)	12 (18.5)	0.001
Remdesivir, n (%)	12 (23.5)	12 (38.7)	19 (20.0)	32 (49.2)	0.004
Barcitinib, n (%)	0 (0)	1 (3.2)	3 (3.2)	1 (1.5)	0.59
Favipiravir, n (%)	7 (13.7)	2 (6.5)	18 (18.9)	6 (9.2)	0.2
Lopinavir-ritonavir, n (%)	0 (0)	1 (3.2)	1 (0.9)	0 (0)	0.08
Tocilizumab, n (%)	2 (3.9)	3 (9.7)	4 (4.2)	9 (13.8)	0.09
Ivermectin, n (%)	1 (2.0)	2 (6.5)	1 (1.1)	0 (0)	0.13
Vitamin C, n (%)	49 (96.1)	29 (93.5)	94 (98.9)	64 (98.5)	0.32
Vitamin D, n (%)	30 (58.8)	21 (67.7)	62 (65.3)	44 (67.7)	0.76
Zinc, n (%)	48 (94.1)	29 (93.5)	92 (96.8)	63 (96.9)	0.75
Azithromycin, n (%)	9 (17.6)	15 (48.4)	43 (45.3)	39 (60.0)	<0.001
Anticoagulant used					
LMWH, n (%)	47 (92.2)	26 (83.9)	77 (81.1)	55 (84.6)	0.36
UFH, n (%)	3 (5.9)	1 (3.2)	3 (3.2)	4 (6.2)	0.77
Fondaparinux, n (%)	0 (0)	2 (6.5)	12 (12.6)	7 (10.8)	0.03
DOACs, n (%)	0 (0)	2 (6.5)	3 (3.2)	0 (0)	0.11

Table 1 Continued

Variables	Prophylactic anticoagulation n=51	Therapeutic anticoagulation n=31	Prophylactic anticoagulation + antiplatelet therapy n=95	Therapeutic anticoagulation + antiplatelet therapy n= 65	P value
Antiplatelet used					
Aspirin, n (%)	0 (0)	0 (0)	93 (97.9)	62 (95.4)	< 0.001
Clopidogrel, n (%)	0 (0)	0 (0)	2 (2.1)	5 (7.7)	0.05
Outcomes					
Composite, n (%)*	8 (15.7)	9 (29.0)	12 (12.6)	34 (52.3)	<0.001
Mortality, n (%)	5 (9.8)	7 (22.6)	6 (6.3)	16 (24.6)	0.004
ICU admission, n (%)	7 (13.7)	8 (25.8)	12 (12.6)	32 (49.2)	<0.001
Invasive ventilation, n (%)	4 (ca)	6 (19.4)	5 (5.3)	19 (29.2)	<0.001
Major bleeding, n (%)	2 (3.9)	2 (6.5)	0 (0)	6 (9.2)	0.17
Clinically relevant non-major bleeds, n (%)	2 (3.9)	1 (3.2)	0 (0)	6 (9.2)	0.29
Minor bleeds, n (%)	1 (2.0)	0 (0)	3 (3.2)	4 (6.2)	0.39
Any thromboembolic event, n (%)	5 (9.8)	9 (38.7)	7 (7.4)	15 (32.3)	0.002
DVT, n (%)	0 (0)	0 (0)	0 (0)	0 (0)	-
PE, n (%)	0 (0)	3 (9.7)	0 (0)	1 (1.5)	0.002
MI, n (%)	0 (0)	0 (0)	2 (2.1)	4 (6.2)	0.12
Ischemic stroke, n (%)	0 (0)	0 (0)	0 (0)	1 (1.5)	0.43

*Composite comprised of either mortality, ICU admissions, or mechanical ventilation.
ACEi/ARB, angiotensin converting enzyme inhibitor/ angiotensin receptor blocker; BNP, brain natriuretic peptide; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; CRP, c-reactive protein; DOAC, direct oral anticoagulant; DVT, deep vein thrombosis; HFNC, high flow nasal canula; ICU, intensive care unit; LMWH, low molecular weight heparin; MI, myocardial infarction; PE, pulmonary embolism; PT, prothrombin time; PTT, partial thromboplastin time; TIA, transient ischemic attack; UFH, unfractionated heparin; VTE, venous thromboembolism; WBC, white blood cells.

bleeding, intraocular bleeding, intra-articular bleeding, pericardial bleeding, spinal bleeding or intramuscular with compartment syndrome. Clinically relevant non-major bleeding was defined as any sign or symptom of bleeding that does not fit the criteria for the ISTH definition of major bleeding but does meet at least one of the following criteria: (1) requiring medical intervention by a healthcare professional; (2) leading to hospitalisation or increased level of care; (3) prompting a face to face evaluation.[29] [30] Minor bleeding was defined as any bleeding sign or symptom of haemorrhage that does not fit the definitions of major bleed and clinically relevant non-major bleed requiring just telephone or electronic communication without needing to see the physician. Criteria for ICU admission was defined as per the Food and Drug Administration as having respiratory failure necessitating invasive or non-invasive mechanical ventilation, shock or multiorgan dysfunction/failure in critically ill COVID-19.[31] Other recorded outcomes related to thrombosis were DVT, PE, stroke, myocardial infarction, and peripheral arterial and other arterial thromboses.

Antithrombotic use definition
At our centre, the use of antithrombotic therapy in patients with COVID-19 was based on international and institution specific guidelines.[27] PAC was the standard of care. Agents used were low molecular weight heparin, unfractionated heparin, fondaparinux or direct oral anticoagulants. Patient with on oral vitamin K antagonists were switched to one of the aforementioned medications to decrease drug–drug interaction risk. Therapeutic dose anticoagulation was chosen when there was an alternative indication for TAC or when the patient was considered at high risk/suspicion of thrombosis without documented evidence due to the limited testing as a result of the COVID-19 situation. D-dimer more than three times the upper limit of normal, worsening oxygen requirements and sudden deterioration were also used as surrogate markers for the use of TAC. Antiplatelet therapy, which consisted of either aspirin or clopidogrel, was added to anticoagulation when the patient was considered at higher risk for CAD based on past medical and social history, age and clinical presentation or was already taking it at home for an alternative indication.

As such, antithrombotic therapy was divided into four subgroups: TAC, PAC +antiplatelet (PACAP), TAC +antiplatelet (TACAP) and PAC which was used as the reference for comparison with the other subgroups.

Outcomes
The time from diagnosis to in-hospital mortality, ICU admission or the need for invasive mechanical ventilation

Table 2 Multivariable Cox regression analysis according to the different antithombotic regimens to define (A) the composite endpoint of ICU admission, invasive mechanical ventilation, and death (B) ICU admission (C) invasive mechanical ventilation (D) in-hospital all cause mortality

	aHR	95.0% CI for aHR		P value
		Lower	Upper	
Composite of ICU admission, invasive mechanical ventilation, and death				
Prophylactic anticoagulation				0.033
Therapeutic anticoagulation	0.84	0.302	2.336	0.738
Prophylactic anticoagulation + antiplatelet therapy	0.505	0.197	1.296	0.155
Therapeutic anticoagulation + antiplatelet therapy	1.434	0.615	3.344	0.404
Hypertension	2.568	1.429	4.617	0.002
Tocilizumab	2.132	1.071	4.244	0.031
Admission oxygen saturation	0.954	0.936	0.973	0
Interlukin-6	1	1	1.001	0.026
Predicted probability anticoagulant prescription	0.528	0.06	4.648	0.565
Predicted probability antiplatelt prescription	1.195	0.282	5.071	0.809
ICU admission				
Prophylactic anticoagulation				0.035
Therapeutic anticoagulation	0.831	0.28	2.466	0.739
Prophylactic anticoagulation + antiplatelet therapy	0.566	0.212	1.515	0.257
Therapeutic anticoagulation + antiplatelet therapy	1.569	0.644	3.821	0.321
Hypertension	2.331	1.284	4.232	0.005
Tocilizumab	2.308	1.154	4.619	0.018
Admission oxygen saturation	0.953	0.934	0.971	0
Interlukin-6	1	1	1.001	0.031
Predicted probability anticoagulant prescription	0.226	0.021	2.386	0.216
Predicted probability antiplatelt prescription	1.412	0.32	6.236	0.649
Invasive mechanical ventilation				
Prophylactic anticoagulation				0.005
Therapeutic anticoagulation	0.629	0.15	2.628	0.525
Prophylactic anticoagulation + antiplatelet therapy	0.07	0.014	0.351	0.001
Therapeutic anticoagulation + antiplatelet therapy	0.359	0.099	1.309	0.121
Gender	5.02	1.911	13.182	0.001
Hypertension	3.343	1.259	8.876	0.015
Steroids	439943.283	0	.	0.978
Admission oxygen saturation	0.888	0.858	0.919	0
Predicted probability anticoagulant prescription	0.005	0	0.177	9.004
Predicted probability antiplatelt prescription	135.695	7.786	2365.045	0.001
D-dimers	1.136	0.994	1.297	0.061
Interlukin-6	1.001	1	1.001	0.001
In hospital all cause mortality				
Prophylactic anticoagulation				0.014
Therapeutic anticoagulation	0.126	0.028	0.573	0.007
Prophylactic anticoagulation + antiplatelet therapy	0.41	0.103	1.634	0.206
Therapeutic anticoagulation + antiplatelet therapy	0.113	0.028	0.449	0.002
Weight	0.974	0.949	1	0.048
Hypertension	3.684	1.211	11.209	0.022

Table 2 Continued

| | aHR | 95.0% CI for aHR | | P value |
		Lower	Upper	
Steroids	73168.344	0	.	0.982
Tofacitinib	2.516	0.872	7.263	0.088
Anticoagulation admission	3.716	1.099	12.571	0.035
Admission oxygen saturation	0.965	0.937	0.994	0.017
Predicted probability anticoagulant prescription	0.947	0.058	15.533	0.97
Predicted probability antiplatelt prescription	6.004	0.641	56.244	0.116
Interlukin-6	1	0.999	1.001	0.877

This Cox regression analysis is adjusted on anticoagulation and antiplatelet regimen, age, smoker, weight, gender, hypertension, dyslipidemia, diabetes, coronary artery disease, steroids, tofacitinib, anticoagulation on admission, immunosuppressant, antiplatelet use on admission, inpatient prescription of any of the following medication, azithromycin, fondaparinux, remdesivir, tocilizumab, oxygen saturation on admission, D-dimers, CRP and interleukin 6, in addition to propensity scores predicted probability of anticoagulant or antiplatelet prescription.
aHR, adjusted hazard ratio; ICU, intensive care unit.

(invasive mechanical ventilation with an endotracheal or tracheostomy tube) were used as the composite primary outcome. The secondary outcomes consisted of the individual events: in-hospital mortality, the need for ICU admissions and the need for invasive mechanical ventilation. The outcomes were collected from the patient's medical records.

Minimal sample size calculation
Given an alpha of 5% and 80% power with nine independent variables in the Cox-proportional hazards model, a minimum of 226 patients would be necessary to fit a parsimonious model adjusting for confounding variables; this minimal sample size was calculated using the G*Power software.

Statistical analysis
Data analysis was performed using SPSS. Bivariate analysis statistics were conducted among treatment subgroups, using Student's t-test (or Mann-Whitney in case of non-normality or non-homogeneous variances) to compare continuous variables between two subgroups, or Kruskal-Wallis test between three subgroups or more, while the χ^2 test (or Fischer's exact if expected count was lower than 5) was used for categorical variables. In all cases, a p value lower than 0.05 was considered significant. Imputation of missing variables for c-reactive protein (CRP), D-dimers and interleukin 6 (IL-6) was used based on the mean. Furthermore, stratification by critical status was not possible, given the small sample size of subgroups.

Survival analysis
Survival analysis was performed to compare the incidence of the composite outcome and individual outcomes between different treatment exposure subgroups, using the Cox regression modelling. For the purpose of survival analysis, the start of the study was taken as admission to the hospital. The endpoint was defined as the composite outcome, the death of the patient during the hospitalisation, being placed on invasive mechanical ventilation, being admitted to the ICU or being discharged alive from the hospital. Patients still hospitalised as of December 2020 were not included for data collection; only patients who were discharged from the hospital or who died during the study period were considered until the end of the study. Survival time in days was calculated as the difference between the date of hospital admission and the date of event occurrence (ICU admission, in-hospital death, mechanical ventilation, composite outcome or discharge from the hospital). Log–log plots and Schoenfeld residuals tested the proportional hazards assumption; there were no violations of the proportionality of hazards assumption.

For the composite and each individual outcome, Cox regressions using a backward method. The model variables were selected on the basis of biological plausibility, previously established in the literature and variables with a p value of 0.2 or less in the bivariate analysis. It included the following variables within the analysis, varying according to the model: anticoagulation and antiplatelet regimen, age, smoker, weight, gender, hypertension, dyslipidaemia, diabetes, coronary artery disease, anticoagulation on admission, immunosuppressant, antiplatelet use on admission, inpatient prescription of any of the following medication, azithromycin, fondaparinux, remdesivir, tocilizumab, steroids, tofacitinib oxygen saturation on admission, D-dimers, CRP and IL-6, in addition to propensity scores (described later). The Enter method was used to force both propensity scores within the models, in case they were removed by the backward analysis. The regression was then used to estimate adjusted HRs (aHRs and their 95% CIs) for associations between treatment exposure status and the composite outcome and each individual outcome in separate models.

Propensity scales calculation

To consider factors driving physicians to prescribe anticoagulants and antiplatelet agents in an observational study setting, propensity scales to predict the prescription patterns for both drugs were calculated. The following variables were selected based on known risk factors affecting patient outcomes affecting antithrombotic therapy in accordance with input from the physicians prescribing the treatment strategies: age, gender, smoking status, body weight, admission heart rate, admission temperature, oxygen saturation on admission, hypertension, dyslipidaemia, congestive heart failure, diabetes, history of bleeding, liver disease, kidney disease, chronic obstructive pulmonary disease, coronary artery disease, previous VTE, platelet count, D-dimer, CRP, troponin, fibrinogen, IL-6 and chronic anticoagulation prior to admission were included in a backward stepwise logistic regression. The probability of prescription, automatically generated by the software, was used as the propensity score (online supplemental material).

RESULTS

Patients characteristics and outcomes

Out of 363 patients with COVID-19 admitted since April 2020, and after applying eligibility criteria and excluding participants with missing information, a total of 242 patients were included for analysis(figure 1). Demographic and clinical characteristics by treatment exposure status are outlined in table 1. All patients received anticoagulation therapy, with more than half being on PAC therapy versus almost 40% on TAC. Antiplatelet therapy was administered to 66.1% of patients, of those, 59.4% were on PACAP and 40.6% were on TACAP. On presentation, 43.4% of patients had dyspnoea as a primary symptom. A significant difference between treatment exposure subgroups was detected by oxygen level saturation (p<0.001) with the lowest oxygen saturation being among patients in the TACAP subgroup. Weight was significantly different among the treatment exposure subgroups, with the average weight being highest in the TACAP subgroup (p=0.039). Moreover, laboratory tests encompassing D-dimer, CRP and IL-6 levels differed between treatment exposure subgroups (p<0.001, p<0.001, p=0.033, respectively), with D-dimer and CRP levels being highest in the TAC subgroup, while IL-6 levels being highest in the TACAP subgroup. During their hospital stay, 92.1% of the patients were placed on steroids, 97.5% on vitamin C, 64.9% on vitamin D and 95.9% received zinc. Days of oxygen requirement were significantly (p<0.001) different among treatment exposure subgroups with a median of 2, 9, 10 and 14 days for the PAC, TAC, PACAP, respectively.

As seen in table 1, composite endpoint that combines mortality, admission to ICU or need for invasive ventilation was reached in 26% of the sample among which 12.7%, 14.3%, 19.1% and 53.9% were in the PAC, TAC, PACAP and TACAP treatment exposure subgroups, respectively. The individual clinical outcomes of mortality, ICU admission, and mechanical ventilation occurred in 14.1%, 24.4% and 14.1%, respectively of the sample. There was no difference in the rates of bleeding observed in the study. Major bleeding occurred in 10 out 242 patients (4.1%) of the study population with no significant difference across the subgroups (p=0.17). Clinically relevant non-major bleeds occurred in 9 out of 242 patients (3.7%) of the study with no significant difference across the treatment subgroups (p=0.39). Thirty-five patients (14.4%) experienced thrombosis during the study period. There was a significant (p=0.002) difference in the occurrence of thrombosis across the study subgroups, PAC 4 out of 51 patients (7.8%), TAC, 9 out of 31 patients (29.0%), PACAP 7 out of 95 patients (7.4%) and TACAP 15 out of 65 patients (23.1%).

Propensity matched multivariable Cox regression analysis results

Results of the multivariable Cox regression analysis showed no significant difference among the three antithrombotic regimens as compared with prophylactic dose with respect to the composite outcome. Higher oxygen saturation on admission showed to be protective. For every 1 unit increase in oxygen saturation on admission patients had a 4.6% decrease in the risk of the composite. Hypertension or being prescribed tocilizumab were significantly associated with an increased risk of experiencing the composite outcome. Elevated IL-6 levels were also associated with a mild but statistically significant increase in the composite (aHR)=1, (95% CI 1.000 to 1.001, p=0.026) (table 2a).

Patients on PACAP had a 93% decreased risk of experiencing invasive mechanical ventilation (aHR=0.070; 95% CI 0.014 to 0.351, p=0.001).(figure 2) For every unit increase in oxygen saturation on admission the risk of invasive mechanical ventilation decreased by 11.2% (table 2c). Elevated IL-6 levels were also associated with a statistically very mild increase in the composite (aHR=1.001, 95% CI 1.000 to 1.001, p=0.001). Hypertension and the female sex were associated with threefold to fivefold increase in the risk of invasive mechanical ventilation, respectively (table 2c).

TAC regimens with or without concurrent antiplatelet use was associated with an 87.4% and 88.7% of decreased risk of mortality, respectively(figure 2). The calculated number needed to treat in both subgroups was 11 (table 2d). However, when TACAP was compared with TAC alone, there was no statistically significant difference in the rates of mortality (16 (24.6%) vs 7 (22.6%), respectively, p=0.809) (online supplemental material).

Higher bodyweight also showed to be protective. For every 1 kg of bodyweight, patients' risk of mortality decreased by 2.6%. Every 1 unit increase of oxygen on admission was associated with a 2.6% decrease in mortality. Both hypertension and prior anticoagulation use on presentation were associated with around a 3.7-fold increase in mortality (table 2d)

The results showed no significant difference among the three antithrombotic regimens as compared with prophylactic dose with respect to the ICU admission rate. Higher oxygen saturation on admission showed to be protective decreasing the risk of ICU admission by 4.7% for every unit of oxygen. Hypertension or being prescribed tocilizumab during hospitalisation were significantly associated with around twice the risk of ICU admission. Elevated IL-6 levels were also associated with a statistically very mild increase in the composite (aHR=1, 95% CI 1.000 to 1.001, p=0.031) (table 2b).

DISCUSSION

In our retrospective study, a propensity matched multivariable Cox regression model demonstrated that the use of concurrent TAC and antiplatelet therapy or TAC alone was associated with improved outcomes in patients hospitalised for COVID-19 infection when compared with patients receiving the standard of care as per current guidelines which is prophylactic dose anticoagulation. A statistically significant reduction in the rate of all-cause in-hospital mortality with no increased rates of major or minor bleeds was found. Furthermore, we demonstrated that PAC plus antiplatelet therapy significantly reduced the rates of invasive mechanical ventilation compared with PAC alone. Importantly, this is the first adequately sized study that clearly dwells on the use of combined anticoagulation and antiplatelet therapy for the treatment of the COVID-19 induced hypercoagulable state.

COVID-19 has been associated with an increased risk of arterial, venous and microvascular thrombosis secondary to endothelial dysfunction with reported cases of heparin resistance.[15] As such, it was no surprise that we observed in our study that therapeutic anticoagulation with or without concurrent antiplatelet use was associated with decreased all-cause mortality when compared with PAC alone. However, after comparing in this study we were unable to discern a difference between TAC to TAC plus antiplatelet. Our results are in line with existing literature. Roomi et al conducted a retrospective cohort consisting of 176 patients admitted to the hospital for COVID-19 infection and reported that TAC was associated with a lower rate of in-hospital mortality compared with PAC (OR 3.05, 95% CI 1.15 to 8.10, p=0.04).[32] Preprint publications by the multiplatform collaborative clinical trial (ACTIV-4a (NCT04505774), REMAP-CAP (NCT02735707), ATTACC (NCT04372589)) that aimed to assess the benefit of full dose anticoagulation to treat non-critically ill or critically ill adults hospitalised for COVID-19, compared with prophylactic dosing showed that TAC had a trend toward less mortality in non-critically ill patients.[33] Moreover, therapeutic dose anticoagulation has also been shown to reduce endothelial cell lesion (p=0.02) which could also reduce the thromboembolic risk of COVID-19, suggesting another therapeutic target for anticoagulants.[34] Our results are not in line with those of Chocron et al who reported no association between various doses of anticoagulation during hospitalisation for COVID-19 infection with an improved outcome.[35] Nevertheless, in the multivariable analysis they performed, they did not account for the use for inpatient treatment agents that have been proven to modify outcomes in patients with COVID-19 such as steroids, remdesivir and tocilizumab.[36–38] IL-6 levels and D-dimer,[39] markers predictive of outcomes in COVID-19, were also not accounted for. As such, this increases the risk of a bias in their analysis of association between anticoagulation and clinical outcome.

PAC plus antiplatelet, mainly aspirin, was found to be associated with a statistically significant reduction in the need for mechanical ventilation when compared with PAC. This observed benefit is probably due to aspirin's established role in decreasing inflammation, reducing platelet-neutrophil aggregates in the lungs and increasing lipoxin formation which restores pulmonary endothelial function.[40] Chow et al demonstrated in a retrospective cohort study that when patients were given aspirin within 24 hours of hospital admission for COVID-19 infection, they had decreased rates of mechanical ventilation (aHR: 0.56; 95% CI 0.37 to 0.85; p=0.007), ICU admission (aHR: 0.57; 95% CI 0.38 to 0.85; p=0.005) and in-hospital mortality (aHR: 0.53; 95% CI 0.31 to 0.90; p=0.02) without increase in major bleeding (p=0.69) or overt thrombosis (p=0.82) in comparison to those who did not receive aspirin.[41] Furthermore, a meta-analysis by Panka et al showed that aspirin is effective in preventing and treating acute respiratory distress syndrome.[40] Our results are in line with a small case–control study where five COVID-19 infected patients were placed on fondaparinux and an antiplatelet therapy regimen (aspirin and/or clopidogrel and a continuous infusion of tirofiban), while controls received prophylactic or therapeutic heparin infusion. Treatment in the combination arm hinted towards improved gas exchange, increase in arterial oxygenation and A-a O2 difference in COVID-19 infected patients.[42] Yet, TAC plus antiplatelet use was not associated with a decrease in mechanical ventilation. This is probably attributed to the fact that the patients with more severe presentations were selected to be given TAC which would falsely hide the benefit of aspirin in lieu of their disease severity. Paranjpe et al reported an increased rate of mechanical ventilation among patients with COVID-19 receiving TAC and attributed this finding to the fact that TAC is reserved for the sicker patients. To note that after adjusting for mechanical ventilation, they found an improved survival in those patients.[24]

We hypothesise that the combined effect of antiplatelet and anticoagulant therapy on COVID-19 induced platelet thrombosis and hypercoagulability, respectively, may result in a synergistic and superior outcome than using either agent alone. Especially since the thrombotic manifestations of COVID-19 are heterogenous and arising from different hypercoagulable mechanisms occurring independently or simultaneously.

Several limitations of this study should be mentioned. Given that this is a retrospective cohort study, association and not causality can be reported between the antithrombotic regimens and outcomes. The sample size was relatively small which makes it difficult to completely adjust for confounding and limits generalisability of the results. Despite efforts to control confounders by using different analytical strategies, some potential biases may have been disregarded, leading to a potential residual confounding. Data are based on the experience of a single centre in Lebanon which prevents generalisability of our findings based on a potential selection bias. Furthermore, thrombotic events may have been underreported due to the strict isolation measures for COVID-19, which may have led treating physicians to underuse imaging for appropriate diagnosis, generating a possible information bias.

Strengths of the study include that it may be one of the first studies to examine the combination of therapies for the management of SARS-CoV-2 to prevent adverse outcomes. In addition, to adjust the analysis for significant variables a propensity matched multivariable Cox regression model was employed. Finally, hazards models that allow time to event analysis accounting for multiple outcomes were employed.

CONCLUSION

In conclusion, this is the first study to demonstrate an improved clinical outcome with the use of combined anticoagulant and antiplatelet therapy in comparison to PAC alone in patients hospitalised for COVID-19 infection with no subsequent increase in minor or major bleeding risk. Furthermore, also TAC was found to be superior to PAC and associated with a better outcome. Prospective randomised controlled trials are needed for the evaluation of the safety and efficacy of combining antiplatelet and anticoagulants agents in the management of patients with COVID-19 and to identify the optimal dosing of anticoagulants.

Author affiliations
[1]Cardiology, Lebanese American University Medical Center-Rizk Hospital, Beirut, Lebanon
[2]Internal Medicine, Lebanese American University Medical Center-Rizk Hospital, Beirut, Lebanon
[3]Department of Pharmacy Practice, Lebanese American University School of Pharmacy, Byblos, Lebanon
[4]Lebanese American University School of Medicine, Byblos, Lebanon
[5]Lebanese University Faculty of Pharmacy, Hadath, Lebanon
[6]University of Nicosia Medical School, Nicosia, Cyprus

ORCID iDs
Nibal Chamoun http://orcid.org/0000-0002-0987-296X
Georges Ghanem http://orcid.org/0000-0002-0850-0689

REFERENCES

1. World Health Organization. Coronavirus disease (COVID-19) pandemic, 2021. Available: https://www.who.int/emergencies/diseases/novel-coronavirus-2019
2. Klok FA, Kruip MJHA, van der Meer NJM, *et al*. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis. *Thromb Res* 2020;191:148–50.
3. Cui S, Chen S, Li X, *et al*. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. *J Thromb Haemost* 2020;18:1421–4.
4. Middeldorp S, Coppens M, van Haaps TF, *et al*. Incidence of venous thromboembolism in hospitalized patients with COVID-19. *J Thromb Haemost* 2020;18:1995–2002.
5. Barbar S, Noventa F, Rossetto V, *et al*. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua prediction score. *J Thromb Haemost* 2010;8:2450–7.
6. Huang C, Wang Y, Li X, *et al*. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020;395:497–506.
7. Wang D, Hu B, Hu C, *et al*. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *JAMA* 2020;323:1061–9.
8. Zhou F, Yu T, Du R, *et al*. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *The Lancet* 2020;395:1054–62.
9. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in china: summary of a report of 72 314 cases from the chinese center for disease control and prevention. *JAMA* 2020;323:1239–42.
10. Ruan Q, Yang K, Wang W, *et al*. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. *Intensive Care Med* 2020;46:846–8.
11. Spiezia L, Boscolo A, Poletto F, *et al*. COVID-19-Related severe hypercoagulability in patients admitted to intensive care unit for acute respiratory failure. *Thromb Haemost* 2020;120:998–1000.
12. Transfusion Medicine and Hemostasis - 3rd Edition. Available: https://www.elsevier.com/books/transfusion-medicine-and-hemostasis/shaz/978-0-12-813726-0 [Accessed 20 Jan 2021].
13. Palta S, Saroa R, Palta A. Overview of the coagulation system. *Indian J Anaesth* 2014;58:515–23.
14. Biswas I, Khan GA. Endothelial dysfunction in cardiovascular diseases. *Basic Clin Underst Microcirc* 2020.
15. Matli K, Farah R, Maalouf M, *et al*. Role of combining anticoagulant and antiplatelet agents in COVID-19 treatment: a rapid review. *Open Heart* 2021;8:e001628.

16 Jin Y, Ji W, Yang H, *et al*. Endothelial activation and dysfunction in COVID-19: from basic mechanisms to potential therapeutic approaches. *Signal Transduct Target Ther* 2020;5:293.

17 Magro C, Mulvey JJ, Berlin D, *et al*. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. *Transl Res* 2020;220:1–13.

18 de Roquetaillade C, Chousterman BG, Tomasoni D, *et al*. Unusual arterial thrombotic events in Covid-19 patients. *Int J Cardiol* 2021;323:281–4.

19 Li W, Xu Z, Xiang H, *et al*. Risk factors for systemic and venous thromboembolism, mortality and bleeding risks in 1125 patients with COVID-19: relationship with anticoagulation status. *Aging* 2021;13:9225–42.

20 Moores LK, Tritschler T, Brosnahan S, *et al*. Prevention, diagnosis, and treatment of VTe in patients with coronavirus disease 2019: chest guideline and expert panel report. *Chest* 2020;158:1143–63.

21 National Institute for Health and Care Excellence (UK). *COVID-19 rapid guideline: reducing the risk of venous thromboembolism in over 16S with COVID-19*. London, 2020. http://www.ncbi.nlm.nih.gov/books/NBK566720/

22 Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC) - Full Text View - ClinicalTrials.gov. Available: https://clinicaltrials.gov/ct2/show/NCT04372589 [Accessed 09 Jan 2021].

23 Tang N, Bai H, Chen X, *et al*. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. *J Thromb Haemost* 2020;18:1094–9.

24 Paranjpe I, Fuster V, Lala A, *et al*. Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19. *J Am Coll Cardiol* 2020;76:122–4.

25 Protective effect of aspirin on COVID-19 patients - full text view - ClinicalTrials.gov. Available: https://clinicaltrials.gov/ct2/show/NCT04365309 [Accessed 09 Jan 2021].

26 Pavoni V, Gianesello L, Pazzi M, *et al*. Venous thromboembolism and bleeding in critically ill COVID-19 patients treated with higher than standard low molecular weight heparin doses and aspirin: a call to action. *Thromb Res* 2020;196:313–7.

27 Cuker A, Tseng EK, Nieuwlaat R, *et al*. American society of hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19. *Blood Adv* 2021;5:872–88.

28 Siegal DM, Barnes GD, Langlois NJ, *et al*. A toolkit for the collection of thrombosis-related data elements in COVID-19 clinical studies. *Blood Adv* 2020;4:6259–73.

29 Schulman S, Angerås U, Bergqvist D, *et al*. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. *J Thromb Haemost* 2010;8:202–4.

30 Kaatz S, Ahmad D, Spyropoulos AC, *et al*. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. *J Thromb Haemost* 2015;13:2119–26.

31 National Institutes of Health. COVID-19 treatment guidelines panel. coronavirus disease 2019 (COVID-19) treatment guidelines, 2019. Available: https://www.covid19treatmentguidelines.nih.gov/

32 Roomi SS, Saddique M, Ullah W, *et al*. Anticoagulation in COVID-19: a single-center retrospective study. *J Community Hosp Intern Med Perspect* 2021;11:17–22.

33 Lawler PR, *et al*, The ATTACC, ACTIV-4a, and REMAP-CAP Investigators. Therapeutic anticoagulation in non-critically ill patients with Covid-19. *medRxiv* 2021.

34 Khider L, Gendron N, Goudot G, *et al*. Curative anticoagulation prevents endothelial lesion in COVID-19 patients. *J Thromb Haemost* 2020;18:2391–9.

35 Chocron R, Galand V, Cellier J, *et al*. Anticoagulation before hospitalization is a potential protective factor for COVID-19: insight from a French multicenter cohort study. *J Am Heart Assoc* 2021;10:e018624.

36 RECOVERY Collaborative Group, Horby P, Lim WS, *et al*. Dexamethasone in hospitalized patients with Covid-19. *N Engl J Med* 2021;384:693–704.

37 Bansal V, Mahapure KS, Bhurwal A. Mortality benefit of Remdesivir in COVID-19: a systematic review and meta-analysis. *Front Med*;2021:606429.

38 RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (recovery): a randomised, controlled, open-label, platform trial. *Lancet* 2021;397:1637–45.

39 Laguna-Goya R, Utrero-Rico A, Talayero P, *et al*. IL-6-based mortality risk model for hospitalized patients with COVID-19. *J Allergy Clin Immunol* 2020;146:799–807.

40 Panka BA, de Grooth H-J, Spoelstra-de Man AME, *et al*. Prevention or treatment of ARDS with aspirin: a review of preclinical models and meta-analysis of clinical studies. *Shock* 2017;47:13–21.

41 Chow JH, Khanna AK, Kethireddy S, *et al*. Aspirin use is associated with decreased mechanical ventilation, intensive care unit admission, and in-hospital mortality in hospitalized patients with coronavirus disease 2019. *Anesth Analg* 2021;132:930–41.

42 Viecca M, Radovanovic D, Forleo GB, *et al*. Enhanced platelet inhibition treatment improves hypoxemia in patients with severe Covid-19 and hypercoagulability. A case control, proof of concept study. *Pharmacol Res* 2020;158:104950.

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

Open Heart

Supplementary Material

Table 3: Mortality model: 2 by 2

	ProphAC	TherAC	ProphAC+AP	TherAC+AP
ProphAC		0.075	0.770	0.003
TherAC	0.075		0.429	0.809
ProphAC+AP	0.770	0.429		0.039
TherAC+AP	0.003	0.809	0.039	

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
placed on this supplemental material which has been supplied by the author(s)

Open Heart

Table 4: Propensity Score for anticoagulation(a) and antiplatelet prescriptioin(b)

   (a) Propensity score for anticoagulation prescription

Variables in the Equation

	B	S.E.	Wald	df	Sig.	Exp(B)	95% C.I.for EXP(B)	
							Lower	Upper
Admission HR	-.028	.010	7.658	1	.006	.973	.954	.992
CHF	1.534	.712	4.638	1	.031	4.637	1.148	18.731

a. Variable(s) entered on step 1: Age, Gender, Smoker, Weight, AdmissionHR, AdmissionTemperature, AdmissionOxygenSaturation, HTN, Dyslipedemia, CHF, Cancer, DM, HistoryBleeding, Liverdisease, KidneyDisease, COPD, CAD, PreviousVTE, PlateletCount, SMEAN(ddimers), SMEAN(CRP), SMEAN(Interleukin6), AnticoagulationAdmission, SMEAN(Fibrinogen), SMEAN(Troponin).

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

Open Heart

(b) Propensity scores for antiplatelet prescription

Variables in the Equation

	B	S.E.	Wald	df	Sig.	Exp(B)	95% C.I.for EXP(B) Lower	Upper
Gender	-.910	.348	6.820	1	.009	.403	.203	.797
Smoker	-.667	.370	3.257	1	.071	.513	.249	1.059
AdmissionTemperature	-.382	.160	5.680	1	.017	.682	.498	.934
COPD	5.439	3.007	3.271	1	.070	230.290	.635	83580.632
SMEAN(ddimers)	-.530	.148	12.782	1	.000	.589	.440	.787
AntiPAdmission	2.772	.720	14.838	1	.000	15.985	3.902	65.495
Constant	9.237	6.494	2.023	1	.155	10271.108		

a. Variable(s) entered on step 1: Age, Gender, Smoker, Weight, AdmissionHR, AdmissionTemperature, AdmissionOxygenSaturation, HTN, Dyslipedemia, CHF, Cancer, DM, HistoryBleeding, Liverdisease, KidneyDisease, COPD, CAD, PreviousVTE, PlateletCount, SMEAN(ddimers), SMEAN(CRP), SMEAN(Interleukin6), AntiPAdmission, SMEAN(Fibrinogen), SMEAN(Troponin).